Manufacturer: Phoenix Pharmaceutical
(levothyroxine Sodium Tablets, Usp)
Each tablet contains either:
|
Levothyroxine sodium USP |
0.1 mg |
|
Levothyroxine sodium USP |
0.2 mg |
|
Levothyroxine sodium USP |
0.3 mg |
|
Levothyroxine sodium USP |
0.4 mg |
|
Levothyroxine sodium USP |
0.5 mg |
|
Levothyroxine sodium USP |
0.6 mg |
|
Levothyroxine sodium USP |
0.7 mg |
|
Levothyroxine sodium USP |
0.8 mg |
Description
Each Levothyroxine Sodium Tablet provides synthetic crystalline levothyroxine sodium (L-thyroxine).
Action
Levothyroxine sodium acts as does endogenous thyroxine, to stimulate metabolism, growth, development and differentiation on tissues. It increases the rate of energy exchange and increases the maturation rate of the epiphyses. Levothyroxine sodium is absorbed rapidly from the gastro-intestinal tract after oral administration. Following absorption, the compound becomes bound to the serum alpha globulin fraction. For purposes of comparison, 0.1 mg. of levothyroxine sodium elicits a clinical response approximately equal to that produced by one grain (65 mg.) of desiccated thyroid.
Thyrozine Tablets Indications
Provides thyroid replacement therapy in all conditions of inadequate production of thyroid hormones. Hypothyroidism is the generalized metabolic disease resulting from deficiency of the thyroid hormones levothyroxine (T-4) and liothyronine (T-3). Levothyroxine sodium will provide levothyroxine (T-4) as a substrate for the physiologic deiodination to liothyronine (T-3). Administration of levothyroxine sodium alone will result in complete physiologic thyroid replacement.
Canine hypothyroidism is usually primary, i.e., due to atrophy of the thyroid gland. In the majority of cases, the atrophy is associated with lymphocytic thyroiditis and in the remainder it is noninflammatory, and as of yet, unknown etiology. Less than 10 percent of the cases of hypothyroidism are secondary, i.e., due to deficiency of the thyroid stimulating hormone (TSH). TSH deficiency may occur as a component of congenital hypopituitarism or as an acquired disorder in adult dogs, in which case it is invariably due to the growth of a pituitary tumor.
Hypothyroidism In The Dog
Hypothyroidism usually occurs in middle-aged and older dogs although the condition will sometimes be seen in younger dogs of the larger breeds. Neutered animals of either sex are also frequently affected, regardless of age. The following are clinical signs of hypothyroidism in dogs: Lethargy, lack of endurance, increased sleeping; Reduced interest, alertness and excitability; Slow heart rate, weak apex beat and pulse, low voltage on ECG; Preference for warmth, low body temperature, cool skin; Increased body weight; Stiff and slow movements, dragging of front feet; Head tilt, disturbed balance, unilateral facial paralysis; Atrophy of epidermis, thickening of dermis; Surface and follicular hyperkeratosis, pigmentation; Puffy face, blepharoptosis, tragic expression; Dry, coarse, sparse coat, slow regrowth after clipping; Retarded turnover of hair(carpet coat of boxers); Shortening of absence of estrus, lack of libido; Dry feces, occasional diarrhea; Hypercholesterolemia; Normochromic, normocytic anemia; Elevated serum creatinine phosphokinase
Contraindications
Levothyroxine sodium therapy is contraindicated in thyrotoxicosis, acute myocardial infraction and uncorrected adrenal insufficiency. Use in pregnant bitches has not been evaluated.
Precautions
The effects of levothyroxine sodium therapy are slow in being manifested. Overdosage of any thyroid drug may produce the signs and symptoms of thyrotoxicosis including, but not limited to, polydipsia, polyuria, polyphagia, reduced heat tolerance and hyperactivity or personality change. Administer with caution to animals with clinically significant heart disease, hypertension or other complications for which a sharply increased metabolic rate might prove hazardous.
Adverse Reactions
There are no particular adverse reactions connected with L-Thyroxine therapy at the recommended dosage levels. Overdose will result in the signs of thyrotoxicosis, listed above under precautions.
Dosage
The initial recommended daily dose is 0.1 mg/10 lb body weight. Dosage is then adjusted according to the patient's response by monitoring T-4 blood levels at time intervals of four weeks.
Administration
Thyroxine tablets may be administered orally or placed in the food.
Dosage Forms Available |
|
0.1 mg - light yellow |
0.5 mg - white |
|
0.2 mg - pink |
0.6 mg - violet |
|
0.3 mg - light green |
0.7 mg - light orange |
|
0.4 mg - light violet |
0.8 mg - light blue |
Tablets in bottles of 180 and 1000.
Thyrozine Tablets Caution
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Storage
Store Between 15° And 30°c (59° And 86°f).
Tightly Close The Container After Each Use.
For Animal Use Only
Keep Out Of Reach Of Children
0.1 mg, 0.3 mg, 0.4 mg, 0.6 mg, 0.7 mg - Manufactured by: Lloyd, Inc., Shenandoah, IA 51601
0.2 mg, 0.5 mg, 0.8 mg - Manufactured by IVX Animal Health, Inc., St. Joseph, MO 64503
Manufactured For: Phoenix Pharmaceutical, Inc., St. Joseph, Mo 64507
801008
801011
801014
Rev1105
|
Net Contents: |
|
NDC |
|
|
180 Tablets |
0.1 mg |
57319-331-31 |
801007 Rev. 06-01 |
|
0.2 mg |
57319-382-31 |
801008 Rev. 0905 |
|
0.3 mg |
57319-333-31 |
801009 Rev. 06-01 |
|
0.4 mg |
57319-334-31 |
801010 Rev. 06-01 |
|
0.5 mg |
57319-385-31 |
801011 Rev0506 |
|
0.6 mg |
57319-336-31 |
801012 Rev. 06-01 |
|
0.7 mg |
57319-337-31 |
801013 Rev. 06-01 |
|
0.8 mg |
57319-388-31 |
801014 Rev0506 |
|
1000 Tablets |
0.1 mg |
57319-331-16 |
801007 Rev. 06-01 |
|
0.2 mg |
57319-382-16 |
801008 Rev. 0905 |
|
0.3 mg |
57319-333-16 |
801009 Rev. 06-01 |
|
0.4 mg |
57319-334-16 |
801010 Rev. 06-01 |
|
0.5 mg |
57319-385-16 |
801011 Rev0506 |
|
0.6 mg |
57319-336-16 |
801012 Rev. 06-01 |
|
0.7 mg |
57319-337-16 |
801013 Rev. 06-01 |
|
0.8 mg |
57319-388-16 |
801014 Rev0107 |
Nac No.
12560844